Repeated Stereotactic Radiotherapy for Local Brain Metastases Failure or Distant Brain Recurrent: A Retrospective Study of 184 Patients.

Date publication

octobre 2023

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine , Pr NOEL Georges , Dr CEBULA Hélène , Dr LE FEVRE Clara

Tous les auteurs :
Kuntz L, Le Fèvre C, Jarnet D, Keller A, Meyer P, Mazzara C, Cebula H, Noel G, Antoni D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37894315

Résumé

The main advantages of stereotactic radiotherapy (SRT) are to delay whole-brain radiotherapy (WBRT) and to deliver ablative doses. Despite this efficacy, the risk of distant brain metastases (BM) one year after SRT ranges from 26% to 77% and 20 to 40% of patients required salvage treatment. The role and consequences of reirradiation remain unclear, particularly in terms of survival. The objective was to study overall survival (OS) and neurological death-free survival (NDFS) and to specify the prognostic factors of long-term survival.

Mots clés

brain metastases, oligorecurrence, radiotherapy, reirradiation, repeated radiosurgery, salvage radiation, stereotactic radiosurgery

Référence

Cancers (Basel). 2023 10 11;15(20):